EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes…